title: Subtherapeutic ocular penetration of caspofungin and associated treatment failure in Candida albicans endophthalmitis.
abstract: Candida endophthalmitis represents the most serious ocular complication of candidemia. The pharmacokinetics and pharmacodynamics of fluconazole, amphotericin B, and flucytosine are fairly well established in endophthalmitis therapy. There remains a paucity of clinical data regarding the utility of new antimycotic agents in the treatment of fungal chorioretinitis and endophthalmitis. We report a case of clinical failure of caspofungin in the management of Candida albicans endophthalmitis associated with poor vitreous penetration.
authors: Department of Medicine, University of Wisconsin-Madison, Madison, WI, USA.
authors: G M
authors: GM
authors: Gauthier
authors: T M
authors: TM
authors: Nork
authors: R
authors: R
authors: Prince
authors: D
authors: D
authors: Andes
mesh_terms: D000328:Adult; D000666:Amphotericin B / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use*; D002177:Candidiasis / Q000188:drug therapy*; D000077336:Caspofungin; D004338:Drug Combinations; D054714:Echinocandins; D009877:Endophthalmitis / Q000188:drug therapy*; D006801:Humans; D055666:Lipopeptides; D008297:Male; D010456:Peptides, Cyclic / Q000627:therapeutic use*; D010713:Phosphatidylcholines / Q000627:therapeutic use; D010715:Phosphatidylglycerols / Q000627:therapeutic use; D017211:Treatment Failure
chemical_list: D000935:Antifungal Agents; D004338:Drug Combinations; D054714:Echinocandins; D055666:Lipopeptides; D010456:Peptides, Cyclic; D010713:Phosphatidylcholines; D010715:Phosphatidylglycerols; C068538:liposomal amphotericin B; D000666:Amphotericin B; D000077336:Caspofungin